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Expression of RMRP RNA is 
regulated in chondrocyte 
hypertrophy and determines 
chondrogenic differentiation
Mandy M. F. Steinbusch1, Marjolein M. J. Caron1, Don A. M. Surtel1, Franziska Friedrich2, 
Ekkehart Lausch2, Ger J. M. Pruijn3, Wouter Verhesen4, Blanche L. M. Schroen4, Lodewijk W. 
van Rhijn1, Bernhard Zabel5 & Tim J. M. Welting1
Mutations in the RMRP-gene, encoding the lncRNA component of the RNase MRP complex, are the 
origin of cartilage-hair hypoplasia. Cartilage-hair hypoplasia is associated with severe dwarfism caused 
by impaired skeletal development. However, it is not clear why mutations in RMRP RNA lead to skeletal 
dysplasia. Since chondrogenic differentiation of the growth plate is required for development of long 
bones, we hypothesized that RMRP RNA plays a pivotal role in chondrogenic differentiation. Expression 
of Rmrp RNA and RNase MRP protein subunits was detected in the murine growth plate and during 
the course of chondrogenic differentiation of ATDC5 cultures, where Rmrp RNA expression was found 
to be correlated with chondrocyte hypertrophy. Genetic interference with Rmrp RNA expression in 
ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on 
hypertrophy and changes in pre-rRNA processing and rRNA levels. Promoter reporter studies showed 
that Rmrp RNA expression responds to chondrogenic morphogens. Chondrogenic trans-differentiation 
of cartilage-hair hypoplasia fibroblasts was impaired with a pronounced impact on hypertrophic 
differentiation. Together, our data show that RMRP RNA expression is regulated during different stages 
of chondrogenic differentiation and indicate that RMRP RNA may play a pivotal role in chondrocyte 
hypertrophy, with potential consequences for CHH pathobiology.
RNase MRP is a small nucleolar ribonucleoprotein (snoRNP) particle, consisting of the RMRP long non-coding 
RNA (lncRNA) and several protein subunits (i.e. Rpp14, Rpp20, Rpp21, Rpp25, Rpp30, Rpp38, Rpp40, 
hPop1, hPop4 and hPop51). RNase MRP is ubiquitously present in eukaryotes and acts as an endoribonucle-
ase which cleaves several RNA substrates. It has been reported to be involved in mitochondrial DNA replica-
tion2, cleaves pre-rRNA in the internal transcribed spacer 1 (ITS1)3, 4, plays a role in cell cycle regulation by 
cleaving cyclin b2 mRNA5, and is able to cleave viperin mRNA6. In addition, it has been shown that RMRP 
RNA and the telomerase-associated reverse transcriptase (TERT) protein are able to form a complex that exerts 
RNA-dependent RNA polymerase activity, which is able to generate a double stranded RMRP RNA molecule. 
Via a Dicer-dependent route siRNAs are generated from this molecule, downregulating cellular RMRP levels 
and providing a negative feedback mechanism controlling RMRP RNA levels7. In addition, RMRP RNA is the 
source of at least two other short RNAs designated RMRP-S1 and RMRP-S2, which function as miRNAs and have 
gene-silencing activity relevant for human cartilage-hair hypoplasia (CHH)8. Recently, RMRP RNA has been 
shown to interact with DDX5 and play a role in RORγt-dependent TH17 biology9. RNase MRP is structurally 
and functionally related to the RNase P endoribonuclease, which has a unique RNA component, but shares many 
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protein subunits with RNase MRP10. RNase P is critically involved in maturation of tRNAs by cleaving the 5′ 
leader of pre-tRNA and is involved in RNA polymerase I and III transcriptional activity11–13.
Mutations in the RMRP gene are the cause of a severe form of dwarfism known as the cartilage-hair hypo-
plasia14 (CHH: OMIM #250250) – anauxetic dysplasia15 (AAD: OMIM #607095) spectrum of disorders16. 
CHH is also termed metaphyseal chondrodysplasia, McKusick-type17. To date, more than hundred individual 
CHH-pathogenic mutations have been identified in the RMRP gene14. These mutations are located either in the 
transcribed region or in the proximal promoter region, often between the TATA box and the transcription start 
site. Promoter mutations may result in inefficient transcription of the RMRP gene, whereas mutations in the 
transcribed region are thought to influence RNase MRP complex assembly, enzymatic activity, subcellular local-
ization, substrate recognition or RNA stability14.
One phenotypic hallmark of CHH is short-limbed dwarfism accompanied by abnormal growth plate develop-
ment. Other symptoms include sparse thin hair, anaemia, Hirschsprung’s disease, bronchiectasis, and impaired 
T-cell immunity. In addition, adult patients have a predisposition to certain cancers (i.e. squamous cell carcinoma, 
basal cell carcinoma and non-Hodgkin lymphoma)16, 18. Longitudinal bone growth during skeletal development 
and lengthening of the limbs depends on endochondral ossification. Endochondral ossification is a multistage 
process in the growth plates of developing long bones. Growth plates are populated by highly proliferative chon-
drocytes, which differentiate into mineralizing hypertrophic chondrocytes that either die from apoptosis or trans-
differentiate into osteoblasts19–21. The remaining mineralized extracellular matrix (ECM) provides a scaffold for 
osteoblasts and osteoclasts to adhere and remodel, setting the stage for bone apposition and thus longitudinal 
bone growth and limb development22, 23. In the proliferative zone of the growth plate, Sox9 drives the expression 
of type II collagen (Col2a1), the main marker for this stage of chondrogenic differentiation. Runx2 and Mef2c 
drive the expression of type X collagen (Col10a1) during the hypertrophic phase of chondrogenic differentiation. 
Many skeletal abnormalities have been described that are often caused by mutations in genes involved in growth 
plate development24.
Although the involvement of the RMRP RNA in the molecular pathology of CHH has been recognized, its 
role in growth plate biology remains elusive. As abnormal growth plate development is one of the radiological 
characteristics of CHH25, and chondrogenic differentiation in the growth plates is required for skeletal develop-
ment23, we hypothesized that the RMRP lncRNA may also function as an important regulator of chondrogenic 
differentiation.
Materials and Methods
In situ hybridization (ISH). Decalcified knee epihyseal growth plates of 6-week-old C57BL/6 mice (use of 
mouse growth plates was approved by the Maastricht University Animal Ethics Committee, according to Dutch 
law; and methods utilized to obtain growth plates were carried out in accordance with Maastricht University 
Animal Ethics Committee and Dutch law) were embedded in paraffin and 5 μm sections were cut. Sections were 
deparaffinized in a xylene/ethanol series ending in PBS (136 mM NaCl (Merck Millipore, Darmstadt, Germany), 
2.7 mM KCl (Merck Millipore), 9.0 mM Na2PO4.H2O (Merck Millipore), 1.8 mM KH2PO4 (Merck Millipore)). 
Antigen retrieval was performed using 20 μg/ml proteinase K (Exiqon, Vedbæk, Denmark). Slides were washed 
extensively with demineralized water to remove proteinase K. Slides were pre-hybridized with microRNA ISH 
buffer (Exiqon; miRCURY LNA microRNA ISH optimization kit FFPE). Hybridization was performed for 1 hour 
at 50 °C on a heating plate using 80 nM of Rmrp RNA double-digoxigenin (DIG)-labeled miRCURY LNA probe 
(5′DIG-CTGACGGATGACGC-3′DIG; custom ordered at Exiqon) or a double-DIG labeled scrambled LNA 
miRNA probe (5′-GTGTAACACGTCTATACGCCCA-3′; Exiqon) in miRNA ISH buffer. Slides were washed 
three times with 5x SSC (0.75 M NaCl, 0.075 M sodium citrate) for 10 minutes at 50 °C. Subsequently slides were 
blocked with blocking solution (DIG Wash and Block buffer set; Roche, Basel, Switzerland) for 30 minutes and 
incubated with anti-DIG-Alkaline Phosphatase (AP) Fab fragments (1:500; Roche) in blocking solution for 
1 hour. Endogenous AP was blocked with Levamisole solution (Vector Laboratories, Burlingame, CA, USA) and 
bound anti-DIG-AP Fab fragments were detected with AP substrate (NBT/BCIP; Roche) in demineralized water. 
Slides were washed in PBS-T (0.1% Tween 20; Sigma-Aldrich, St. Louis, MO, USA), counter-stained with 0.01% 
FastGreen (Sigma-Aldrich), dehydrated and mounted with Entellan (Merck Millipore).
Immunohistochemistry (IHC). Knee joint epiphyseal growth plates of 6-week-old C57BL/6 mice were 
formalin-fixed and decalcified using 0.5 M ethylenediaminetetraacetic acid (EDTA; VWR Prolabo, Amsterdam, 
the Netherlands), pH 7.8. After paraffin-embedding 5 μm tissue sections were cut. Sections were deparaffinized in 
a xylene/ethanol series ending in PBS. For antigen retrieval (COL10A1 detection) sections were treated with 0.4% 
hyaluronidase (Sigma-Aldrich) at 37 °C for 30 minutes. Sections for detection of RNase MRP protein subunits 
were incubated in hot citrate buffer (1.8 mM citric acid (Sigma-Aldrich) and 8.2 mM tri-sodium citrate (VWR 
Prolabo)) for 30 minutes. Endogenous peroxidase activity was inactivated using peroxidase-blocking solution 
(Dako, Troy, MI, USA). Next, slides were blocked with 10% normal sheep serum in PBS-T. Primary antibodies 
were incubated for 1 hour at room temperature. Rabbit polyclonal anti-COL10A126 was used at a 1:1,000 dilution. 
Rabbit polyclonal anti-Rpp2527, anti-Rpp3028, anti-Rpp3828, anti-Rpp4029 and anti-hPop130 were used at a 1:100 
dilution. Bound antibodies were detected with horseradish peroxidase (HRP)-conjugated anti-rabbit secondary 
antibodies (Dako EnVision) for 30 minutes at room temperature. DAB chromogen substrate (Dako) was used for 
detection. Sections were counterstained with haematoxylin (Dako), dehydrated and mounted with histomount 
(Thermo Shandon, Waltham, MA, USA). Microscopic images were acquired using a Zeiss Axioscope A1.
Cell culture and differentiation of ATDC5 and MCT cells and siRNA transfection. ATDC5 cells31 
were cultured in a humidified atmosphere at 37 °C, 5% CO2 in proliferation medium (DMEM/F12 (Invitrogen, 
Carlsbad, CA, USA), 5% FCS (PAA, Pasching, Austria), 1% antibiotic/antimycotic (Invitrogen), 1% NEAA 
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(Invitrogen)). To induce chondrogenic differentiation, cells were plated at 6,400 cells/cm2. After 24 hours chon-
drogenic differentiation was initiated by changing the medium to differentiation medium (proliferation medium 
supplemented with 10 μg/ml insulin (Sigma-Aldrich), 10 μg/ml transferrin (Roche), 30 nM sodium selenite 
(Sigma-Aldrich)). Differentiation medium was refreshed every two days for the first 10 days, and each day after 
day 10. Chondrogenically differentiating ATDC5 cells were transfected (Icafectin; Eurogentec, Seraing, Belgium) 
with 100 nM siRNA duplexes (custom synthesized by Eurogentec, see Table 1) targeting Sox9, Bapx1 or Rmrp 
RNA on day -1, 2, and 5 during differentiation in the presence or absence of 30 nM BMP-2 (Life Technologies, 
Carlsbad, CA, USA). Scrambled siRNA duplex was purchased from Eurogentec (REF: SR-CL000–005). Cells were 
harvested for RNA isolation on day 0, 7 and 10 during differentiation (TRIzol reagent; Invitrogen) and samples 
were kept at −80 °C until further analysis. In addition, ATDC5 cells were differentiated for 14 days and exposed to 
5 or 50 nM PTHrP (Bachem, Bubendorf, Switzerland) from day 10 onwards (medium with PTHrP was refreshed 
on day 12 during chondrogenic differentiation). MCT cells32 were cultured in a humidified atmosphere at the 
permissive temperature of 32 °C, 8% CO2 in proliferation medium (DMEM/F12 (Invitrogen), 10% FCS (PAA), 
1% antibiotic/antimycotic (Invitrogen), 1% NEAA (Invitrogen)). Hypertrophic differentiation was induced in the 
absence or presence of 50 nM PTHrP (Bachem) by switching culture conditions to 37 °C, 5% CO2 for 24 hours. 
Cells were harvested for RNA isolation (TRIzol reagent; Invitrogen) and samples were kept at −80 °C until further 
analysis. To maintain Rmrp knockdown during an extended period of time during chondrogenic differentiation, 
scrambled (Eurogentec SR-CL000-005) and Rmrp RNA (Table 1) siRNAs were either transfected on day 2 and 5 
of ATDC5 chondrogenic differentiation for read-out at day 7 or on day 2, 5 and 8 in chondrogenic differentiation 
for read-out at day 14.
Description of plasmids, transfection and bioluminescence detection. Plasmid constructs were 
generated using traditional cloning methods and cloned inserts were verified by DNA sequencing. The mouse 
1500 nucleotide sequence upstream of the mouse Rmrp transcription start site was amplified from ATDC5 
genomic DNA and cloned into the pGluc-Basic vector (NEB) using primer-introduced restriction sites EcoRV 
and HindIII (pGluc-Rmrp-prom). As a transfection control the pGL4.20[luc2/Puro] (Promega, Southampton, 
UK) vector was used in which the CMV promoter was cloned (pGL4.20[luc2/Puro]-CMV). Day 5-differentiating 
ATDC5 cells in 12 well plates were transfected with 500 ng pGluc-Rmrp-prom and 125 ng pGL4.20[luc2/
Puro]-CMV using 1 μg/μl polyethylenimine (PEI; Polysciences, Warrington, PA, USA) transfection reagent. DNA 
and PEI were complexed for 10 minutes at room temperature in DMEM/F12 (1.9 μl PEI per 625 ng construct 
per well) and added to the ATDC5 cells. Five hours post-transfection medium was supplemented with BMP-2 
(30 ng/ml; Life Technologies), PTHrP (100 nM; Bachem), TGF-β3 (10 ng/ml; Life Technologies), dorsomor-
phin (10 μM; Santa Cruz Biotechnology, Dallas, TX, USA), (5Z)-7-Oxozeaenol (0.5 μM; Merck Millipore), SHH 
(150 ng/ml; R&D systems, Minneapolis, MN, USA), IHH (150 ng/ml; R&D systems), WNT5A (15 ng/ml; R&D 
systems), WNT3A (15 ng/ml; Peprotech, Rocky Hill, NJ, USA), GDF-5 (100 ng/ml; Peprotech) and bFGF (15 ng/
ml; Peprotech). After 36 hours samples were harvested for bioluminescence detection using the Dual Luciferase 
reporter assay system (Promega) as described by the manufacturer and measured on a Fluostar Omega plate 
reader (BMG Labtech, Ortenberg, Germany).
RT-qPCR. RNA was isolated from TRIzol samples by collecting the aqueous phase after phase separation. 
RNA was precipitated with isopropanol (30 minutes, −80 °C) and centrifuged for 30 minutes at 20,000 × g, 4 °C. 
RNA pellets were washed with 80% ethanol and potential DNA contamination was removed by DNase I (Roche) 
treatment (1 hour, 37 °C). After subsequent ethanol precipitation, RNA was dissolved in 15 μL DNase/RNase free 
water (Eurogentec). RNA quantity and purity were determined spectrophotometrically (Biodrop, Isogen Life 
Sciences, Utrecht, the Netherlands). DNA-free total RNA was reverse transcribed using standard procedures and 
random hexamer priming as described previously33. Real time quantitative PCR (RT-qPCR) was performed in 
96-well optical plates. For each cDNA sample a mix was prepared consisting of Mesagreen qPCR Mastermix Plus 
for SYBR Green (Eurogentec) and 300 nM forward and reverse oligonucleotides. Serially diluted standard curves 
were utilized to quantify gene expression in the samples. A Biorad CFX96 Real-Time PCR Detection System was 
used for amplification using the following protocol: denaturation at 95 °C for 10 minutes, followed by 50 cycles of 
amplification (15 seconds 95 °C and 1 minute 60 °C) followed by a dissociation curve. Data were analyzed using 
Biorad CFX Manager Software version 3.1, based on the relative quantification of mRNA expression of the target 
gene normalized to a housekeeping gene (ATDC5/MCT: β-actin, human fibroblasts: GAPDH). Primer sequences 
are depicted in Table 2.
Cell staining protocols and assays. Crystal Violet, Alcian Blue and Alizarin Red S staining and quantifica-
tion. Cells were washed two times with 0.9% NaCl and fixed with 4% paraformaldehyde in PBS for 10 minutes 
at room temperature. Fixed cells were washed 6 times with distilled water and air-dried. Dried fixed cells were 
incubated for 30 minutes at room temperature with either 0.1% (m/v) Crystal Violet (Sigma-Aldrich); 1% (m/v) 
Alcian Blue (Acros Organics, Geel, Belgium) in 0.1 M HCl; or 40 mM Alizarin Red S (Sigma-Aldrich), pH 4.2. 
siRNA Sense Anti-sense
siSox9 GACUCACAUCUCUCCUAAUTT AUUAGGAGAGAUGUGAGUCTT
siBapx1 CAGAGACGCAAGUGAAGAUTT AUCUUCACUUGCGUCUCUGTT
siRmrp RNA CAUGUUCCUUAUCCUUUCGTT CGAAAGGAUAAGGAACAUGTT
Table 1. siRNA sequences.
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Cells were washed six times with distilled water to remove unbound stain and allowed to air dry. Pictures were 
acquired with an Epson V370 flatbed scanner (Epson, Nagano, Japan). Crystal Violet was extracted by incubation 
with 10% acetic acid (VWR) for 15 minutes on a plate shaker (IKA HS 260 Basic, IKA, Staufen, Germany). Alcian 
Blue was extracted by incubation with 6 M Guanidine-HCl (Sigma-Aldrich) for 2 hours on a plate shaker (IKA). 
Alizarin Red S extraction was initiated by incubation with 10% acetic acid (VWR Prolabo) for 30 minutes at room 
temperature on a plate shaker (IKA). Cells and eluate were further collected using a cell scraper and transferred to 
a microcentrifuge tube. Samples were heated at 85 °C for 10 minutes and subsequently centrifuged at 20,000 × g 
for 15 minutes at 4 °C. Ammonium hydroxide (VWR) was added to neutralize the acetic acid until a pH of 4.4 
was reached. Extracted Crystal Violet, Alcian Blue and Alizarin Red S were quantified spectrophotometrically at 
590 nm, 645 nm or 405 nm (respectively) using a plate reader (ThermoScientific Multiskan FC, Waltham, MA, 
USA).
ALP activity assay. Enzymatic activity of Alkaline Phosphatase in ATDC5 cultures was determined in a color-
imetric assay. Cells were lysed in lysis buffer (1.5 M Tris-HCl, pH 9.0; 2% v/v Triton X-100) and homogenized 
on ice by means of sonication (MSE Soniprep 150, Gemini, Apeldoorn, the Netherlands). Insoluble material was 
removed by centrifugation (5 minutes, 13,000 at 4 °C). Total protein concentration was determined with a BCA 
assay (Sigma-Aldrich). In flat-bottom 96 wells plates containing assay buffer (1.5 M Tris-HCl, pH 9.0, 1 mM 
MgCl2; 7.5 mM p-nitrophenyl phosphate), ALP activity was determined by measuring ALP-dependent enzymatic 
conversion of p-nitrophenyl phosphate to nitrophenyl phosphate by spectrophotometric analysis at 405 nM. A 
calibration curve containing an increasing concentration of nitrophenyl phosphate was used to determine the 
absolute amount of ALP-generated nitrophenyl phosphate over time. Values were normalized to total protein 
concentration and ALP activity expressed as µmol nitrophenyl phosphate/gram/minute.
Chondrogenic trans-differentiation of human dermal fibroblasts. Ethical permission for the use 
of dermal fibroblasts was obtained from the medical ethical Institutional Review Board of Freiburg University 
Hospital and methods and experimental protocols to obtain dermal fibroblasts were carried out in accordance 
with the Freiburg University Hospital medical ethical Institutional Review Board, according to German law. 
Informed consent was obtained from all subjects. Human dermal fibroblasts (passage 7–9) were hyperconfluently 
plated (100,000 cells/cm2) in Aggrecan-coated (Sigma-Aldrich; 2.5 μg/cm2) wells as previously described34. Cells 
were directly plated in trans-differentiation medium which consisted of DMEM/F12 + Glutamax (Invitrogen), 
Gene Forward Reverse
β-Actin CCGAGCGCGAGATCGT TGGCCATCTCGTTCTCGAA
Aggrecan CATGAGAGAGGCGAATGGAA TGATCTCGTAGCGATCTTTCTTCT
Alpl (Mm) CCGATGGCACACCTGCTT GGAGGCATACGCCATCACAT
ALPL (Hs) CCGTGGCAACTCTATCTTTGG CAGGCCCATTGCCATACAG
Bapx1 ACCTGGCAGCTTCGCTGAA AGGTCGGCGGCCATCT
Col2a1 (Mm) TGGGTGTTCTATTTATTTATTGTCTTCCT GCGTTGGACTCACACCAGTTAGT
COL2A1 (Hs) TGGGTGTTCTATTTATTTATTGTCTTCCT GCGTTGGACTCACACCAGTTAGT
Col10a1 (Mm) CATGCCTGATGGCTTCATAAA AAGCAGACACGGGCATACCT
COL10A1 (Hs) ATGATGAATACACCAAAGGCTACCT ACGCACACCTGGTCATTTTCTG
Clb2 TGCCAAGCTTTCTCTGATGCT GGGTTCTCCCTGTCCTCGTT
GAPDH (Hs) ACTTTGTGAAGCTCATTTCCTGGTA GTGGTTTGAGGGCTCTTACTCCTT
ITS1 (Mm) TGGGGGGGTGGATGTCTGGAG CGAGTGATCCACCGCTAAGAGTCGTA
ITS1 (Hs) TGTGAAACCTTCCGACCCCTCT CGAGTGATCCACCGCTAAGAGTCGTA
Mef2c GGGCCTCAATGGCTGTGA CTCAGACTCAGGGCTGTGACCTA
Osteocalcin GCGGCCCTGAGTCTGACA GCCGGAGTCTGTTCACTACCTT
Pop4 GGACACGCAGCCACAGATG TGACTGAAATAATAGCACCATGAAGAT
Pthrp (Mm) GTTCAGCAGTGGAGTGTC GATGGTGGAGGAAGAAACG
PTHrP (Hs) AAGGGCAAGTCCATCCAAGA CTCGGCGGTGTGTGGATTTC
Rmrp (Mm) ATACGAGGGACATGTTCCTTATCC TTGGCGGGCTAACAGTGACT
RMRP (Hs) GAGAGTGCCACGTGCATACG ACGCTTCTTGGCGGACTTT
Rpp30 TCAAAAGACCCCCTGTTAATGTG GATAGCAGGACCATAGACAAGTTCAA
Rpp40 TGTGTCACTACTTCGATGAACCAA TGTCTGCAAAGCCTTGAACTGT
Runx2 GACGAGGCAAGAGTTTCACC GGACCGTCCACTGTCACTTT
5.8S rRNA CACTCGGCTCGTGCGTCGAT CGCTCAGACAGGCGTAGCCC
18S rRNA AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC
28S rRNA GCCATGGTAATCCTGCTCAGTAC GCTCCTCAGCCAAGCACATAC
Sox9 AGTACCCGCACCTGCACAAC TACTTGTAGTCCGGGTGGTCTTTC
Viperin TGCTATCTCCTGCGACAGCTT CCTTGACCACGGCCAATC
Table 2. RT-qPCR primer sequences. When not specified, primer sequences were designed for Mus musculus. 
In table Mus musculus is abbreviated as Mm and Homo sapiens as Hs.
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10% FCS (PAA), 1% antibiotic/antimycotic (Invitrogen), 1% NEAA (Invitrogen) + 1% ITS (Insulin, Transferrin, 
Selenium-Sodium Pyruvate; Life Technologies), 50 μg/ml ascorbic acid 2-phosphate (Sigma-Aldrich) and 
1 ng/ml human recombinant TGF-β3 (Life Technologies). Trans-differentiation medium was refreshed every 
other day and transdifferentiated cartilaginous nodules were harvested in TRIzol on day 3, 5 and 7 during 
trans-differentiation. At plating, fibroblasts were harvested for day 0 samples as well.
Results
Rmrp RNA and RNase MRP protein subunits are differentially expressed in the developing 
growth plate. To investigate RMRP RNA expression during chondrogenic differentiation of the growth plate, 
5 μm tissue sections were prepared from growth plates of 6 weeks-old mice. Expression of Rmrp RNA was deter-
mined by in situ hybridization (Fig. 1A). Resting zone chondrocytes express Rmrp RNA and weak expression was 
observed in the chondrocytes of the proliferative zone. The highest expression levels of Rmrp RNA were detected 
in the hypertrophic zone. Cells in the remodeling zone of the growth plate (osteoclasts and osteoblasts) were also 
positive for the expression of Rmrp RNA. Subsequently, we evaluated the spatiotemporal expression of a number 
of RNase MRP protein subunits RPP25, RPP30, RPP38, RPP40 and POP1 (Fig. 1B). Expression of COL10A1 was 
immunohistochemically detected to visualize the location of the hypertrophic zone (Fig. 1B). Without excep-
tion, all RNase MRP protein subunits tested displayed a spatiotemporal growth plate distribution pattern highly 
similar to Rmrp RNA; resting zone chondrocytes express RNase MRP subunits, whereas weak expression was 
observed in chondrocytes of the proliferative zone. Highest RNase MRP protein subunit expression levels were 
detected in the hypertrophic zone of the developing growth plate.
Rmrp RNA expression is induced during ATDC5 chondrogenic differentiation. To study RMRP 
RNA expression in a model for chondrogenic differentiation we used the ATDC5 cell line31. ATDC5 cells follow 
a defined chondrogenic differentiation program after stimulation with insulin, transferrin and sodium selenite. 
The induction of Col2a1 expression at day 7 during differentiation marks chondrogenic differentiation. At 14–21 
days during differentiation cells have acquired a predominant hypertrophic/mineralizing phenotype as indicated 
by co-expression of Col10a1, and at day 21 mineralization becomes evident by expression of osteocalcin (Fig. 2A). 
Figure 1. Spatiotemporal expression of Rmrp RNA and RNase MRP subunits in the growth plate. Five 
micrometer-thick formalin-fixed paraffin-embedded tissue sections were prepared from knee joint epiphyseal 
growth plates of 6-weeks-old mice. (A) Expression of Rmrp RNA was detected by in situ hybridization. A 
scrambled probe was used as control. (B) The expression of COL10A1 and RNase MRP protein subunits RPP25, 
RPP30, RPP38, RPP40 and POP1 was detected immunohistochemically. Figure shows representative images of 
the ISH (A) IHC (B) results from three individual experiments each.
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Expression of Rmrp RNA was slightly upregulated at day 7 in chondrogenic differentiation, increased further at 
day 14 in differentiation and showed highest levels at day 14 and 21 in differentiation, predominantly coinciding 
with peak Col10a1 expression. Rmrp RNA expression decreased again at day 28 during differentiation (Fig. 2B). 
Expression of RNase MRP protein subunits Rpp30 and Rpp40 showed a similar pattern with the highest levels 
of expression at day 14 and 21 during differentiation (Fig. 2B). Together, these data show that the expression of 
Rmrp RNA responds to induction of chondrogenic differentiation with highest expression levels late in the dif-
ferentiation program.
Rmrp expression is positively correlated with the hypertrophic phenotype of the chondro-
cyte. Above data indicate that RMRP RNA expression is associated with late phase/hypertrophic chondro-
genic differentiation. Therefore we next asked whether RMRP RNA expression adapts to a changing chondrocyte 
hypertrophic phenotype. To drive differentiating ATDC5 cells towards a hypertrophic phenotype we reduced the 
expression of Sox9 or Bapx1 by targeting the corresponding mRNAs by siRNA-mediated knockdown. In line with 
previous reports and work from our group33, 35–37, knockdown of Sox9 expression (Fig. 3A) resulted in reduced 
expression of chondrogenic markers Bapx1 (Fig. 3B), Col2a1 (Fig. 3C) and Aggrecan (Fig. 3D) and concomitantly 
increased expression of hypertrophic markers Runx2 (Fig. 3E), Mef2c (Fig. 3F) and Col10a1 (Fig. 3G), which is 
consistent with a prominent hypertrophic chondrocyte phenotype. As a result of Sox9 knockdown, the expres-
sion of Rmrp RNA (Fig. 3H) was increased. We previously reported35 that knockdown of the key hypertrophic 
repressor Bapx1 (Fig. 3B) does not influence the expression of chondrogenic factors Sox9, Col2a1 and Aggrecan 
(Fig. 3A,C,D). Instead, a selective hypertrophic chondrocyte phenotype was provoked, as evidenced by increased 
expression of hypertrophic markers Runx2, Mef2c and Col10a1 (Fig. 3E–G). Similar to what was observed for 
Sox9 knockdown, preferential hypertrophic differentiation by knockdown of Bapx1 expression led to increased 
expression of Rmrp RNA (Fig. 3H). Increased hypertrophy was also observed when ATDC5 cells were exposed 
to the hypertrophic inducer BMP-236, as evidenced by induced expression of hypertrophic markers. Under these 
conditions, the expression of Rmrp RNA was also induced (Fig. 3H). To further investigate Rmrp induction by 
chondrocyte hypertrophy, ATDC5 cell were differentiated for 14 days to induce a hypertrophic phenotype. To 
counteract hypertrophy, cultures were exposed to PTHrP from day 10 in differentiation onwards23, 38. Addition of 
PTHrP reduced the induction of the hypertrophic markers Runx2 (Fig. 4A) and Col10a1 (Fig. 4B). As a result of 
PTHrP-mediated reduction of hypertrophy, Rmrp RNA expression was downregulated as well (Fig. 4C). To con-
firm the PTHrP-mediated reduction of Rmrp RNA expression in another hypertrophic chondrocyte model, we 
used MCT cells. MCT cells are mouse chondrocytes, immortalized with a temperature-sensitive simian virus 40 
large tumor antigen. These cells proliferate at 32 °C, but terminally differentiate and become hypertrophic within 
Figure 2. Rmrp RNA and RNase MRP subunit expression responds to chondrogenic differentiation of ATDC5 
cells. ATDC5 cells were differentiated in the chondrogenic lineage for 0, 7, 14, 21 or 28 days. (A) Different 
stages of chondrogenic differentiation were confirmed by measuring gene expression of Col2a1, Col10a1 and 
osteocalcin. (B) Expression of Rmrp RNA and RNase MRP protein subunits Rpp30 and Rpp40 is depicted as 
fold induction relative to t = 0. Data was normalized to β-actin and represents the average value of 3 biological 
replicates plus standard deviation. For statistical evaluation an independent samples t-test was performed 
between each consecutive time point using GraphPad Prism 5. p-values are indicated. Presented graphs are 
representative examples of three independent experiments.
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24 hours at 37 °C32. As expected, culturing MCT cells at 37 °C induced hypertrophic differentiation as indicated 
by upregulation of Runx2 and Col10a1 expression (Fig. 4D,E). Rmrp RNA expression was also upregulated in this 
hypertrophic cell model (Fig. 4F). When the hypertrophic MCT phenotype was suppressed by PTHrP (Fig. 4D,E), 
Rmrp RNA expression responded similarly (Fig. 4F). Overall, our data indicate a positive correlation between 
Rmrp RNA expression levels and chondrocyte hypertrophy.
Chondrogenic morphogens alter Rmrp promoter activity. Our data described above suggested that 
RMRP RNA expression may be responsive to common chondrogenic morphogens, for example via modulation 
of proximal promoter activity. To acquire a broader understanding of chondrogenic pathways that may influence 
RMRP RNA expression, ATDC5 cells were transfected with a Gaussia luciferase reporter, driven by the 1500 
nucleotide sequence upstream of the mouse Rmrp transcription start site (pGluc-Rmrp-prom plasmid) and cells 
were exposed to different chondrogenic mediators (Fig. 5). PTHrP keeps chondrocytes in a proliferative state 
and counteracts hypertrophic differentiation23, 38. PTHrP decreased Rmrp promoter activity by 18%. bFGF (or 
FGF2), a negative regulator of chondrocyte hypertrophic maturation39, reduced Rmrp promoter activity by 35%. 
TGFβ isoforms activate SMAD signaling via SMAD2/340. Of all TGFβ isoforms, TGFβ3 was described to be able 
to induce matrix mineralization41. Indeed, TGFβ3 increased Rmrp promoter activity by 40%. In agreement with 
the TGFβ3-induced increase of Rmrp promoter activity, exposure to (5Z)-7-Oxozeaenol, an inhibitor of TGF-β 
activated kinase-1 (TAK1)42, decreased Rmrp promoter activity by 22%. Exposure to BMP-2 (pro-hypertrophic, 
see Fig. 3) increased Rmrp promoter activity by 105%, whereas dorsomorphin, an inhibitor of BMP-mediated 
SMAD1/5/8 phosphorylation43, decreased Rmrp promoter activity by 76%. GDF-5 (a BMP family member 
described to induce both chondrogenic differentiation and hypertrophy44 did not significantly change Rmrp pro-
moter activity. WNT-3A and WNT-5A, two prominent ligands of the Wnt signaling pathway and crucial in chon-
drocyte differentiation45, increased Rmrp promoter activity by 45% and 26%, respectively. Finally, Sonic Hedge 
Hog (SHH), the main ligand that activates Patched-1-mediated GLI-signaling and which is crucial in limb bud 
patterning during embryogenesis46, did not significantly alter promoter activity. We thus concluded that the 1500 
nucleotide sequence upstream of the Rmrp RNA transcription start site is responsive to mediators known to alter 
the chondrocyte phenotype. This indicates that, in chondrocytic cells, Rmrp RNA levels may be controlled by 
transcription factors involved in chondrocyte differentiation and hypertrophy.
Figure 3. Rmrp RNA expression increases with ATDC5 hypertrophic differentiation. ATDC5 cells were 
transfected with 100 nM siRNA duplexes targeting Sox9 or Bapx1 gene expression on day -1, day 2, and day 
5 during chondrogenic differentiation. A scrambled siRNA duplex purchased from Eurogentec was used as 
control condition for both Sox9 or Bapx1 knockdown. In addition, ATDC5 cells transfected with the scrambled 
siRNA were exposed to 30 ng/ml BMP-2 from the start of differentiation (cells from the BMP-2 condition were 
also transfected with the negative control scrambled siRNA in order to make all three interventions (Sox9 
knockdown, Bapx1 knockdown and exposure to BMP-2) technically comparable to the same control). RNA 
was isolated from these cultures at day 10 in differentiation. Gene expression of Sox9 (A), Bapx1 (B), Col2a1 
(C), Aggrecan (D), Runx2 (E), Mef2c (F), Col10a1 (G) and Rmrp RNA (H) was determined by RT-qPCR. 
Gene expression is depicted as fold induction relative to t = 0. Data was normalized to β-actin expression and 
represents the average values of 3 biological replicates plus standard deviation. For statistical evaluation an 
independent samples t-test was performed relative to control using Graphpad Prism 5. p-values are indicated. 
Experiment was performed three times with presented graphs being representative examples.
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Rmrp RNA knockdown deregulates chondrogenic differentiation of ATDC5 cells. To investi-
gate whether RMRP RNA regulates chondrogenic differentiation, Rmrp RNA expression was targeted by RNAi. 
ATDC5 cells were transfected with an siRNA duplex at day -1, 2 and 5 during chondrogenic differentiation and 
gene expression was determined at day 0, 7 and 10 in differentiation. The siRNA duplex reduced the expression of 
Rmrp RNA significantly (Fig. 6A). To confirm that this led to a functional reduction of RNase MRP activity, the 
expression of substrate RNAs for RNase MRP, i.e. Clb2 mRNA, Viperin mRNA and ITS1 pre-rRNA, were meas-
ured4–6. Reduced Rmrp RNA levels indeed resulted in elevated levels of RNase MRP substrates Clb2 and Viperin 
mRNAs, as well as an accumulation of an ITS1 pre-rRNA processing intermediate. (Fig. 6B–D). Following Rmrp 
knock-down, expression of Sox9 (Fig. 6E), Col2a1 (Fig. 6F), Runx2 (Fig. 6G), Col10a1 (Fig. 6H) and Alpl (Fig. 6I) 
was reduced at both 7 and 10 days in differentiation. Overall, expression of Runx2, Col10a1 and Alpl seemed to be 
more heavily affected than Col2a1. In accordance, Bapx1 mRNA was strongly induced (Fig. 6J), which is indica-
tive of deregulated hypertrophic differentiation35. These data show that reduction of Rmrp RNA levels impacts the 
course of chondrogenic differentiation, with a prominent impact on the hypertrophic differentiation program. In 
concordance with the observed deregulated chondrogenic differentiation, expression of Pthrp was increased after 
Rmrp RNA knockdown (Fig. 6K). Since RNase MRP has been shown to be implicated in pre-rRNA processing3, 4, 
we assessed the levels of 18 S, 5.8 S and 28 S following Rmrp RNA knockdown and we observed reduced levels of 
18 S and 5.8 S, but not of 28 S rRNAs at day 7 in ATDC5 chondrogenic differentiation (Fig. 6L).
Rmrp RNA knockdown affects cell proliferation, glycosaminoglycan content and mineraliza-
tion of ATDC5 cells. We next investigated whether deregulation of chondrogenic differentiation by Rmrp 
RNA knockdown is accompanied by functional changes of the chondrogenic differentiation program at different 
Figure 4. Hypertrophy-associated Rmrp RNA expression is reduced by PTHrP. ATDC5 cells were differentiated 
for 14 days to create a hypertrophic phenotype and 5 or 50 nM PTHrP was added from day 10 in chondrogenic 
differentiation onwards. Gene expression of Runx2 (A) and Col10a1 (B) and Rmrp RNA (C) was analyzed 
by RT-qPCR. Data was normalized to β-actin, represents the average of value of 3 individual samples plus 
standard deviation and is depicted as fold induction relative to day 0 ATDC5 cells. For statistical evaluation 
an independent samples t-test was performed relative to day 14 control ATDC5 cells using Graphpad Prism, 
where *= p < 0.05. MCT cells were plated and cultured at the permissive temperature of 32 °C and hypertrophic 
differentiation was induced by incubating the cells at 37 °C in the absence or presence of 50 nM PTHrP. Total 
RNA was isolated 24 hours after the temperature shift and analyzed for Runx2 (D), Col10a1 (E) and Rmrp 
RNA (F) expression by RT-qPCR. Data was normalized to β-actin, represents the average value of 4 biological 
replicates plus standard deviation and is depicted as fold-induction relative to the permissive temperature 
of 32 °C. For statistical evaluation an independent samples t-test was performed between the permissive 
temperature and induction of hypertrophic differentiation and between hypertrophic induction in the absence 
or presence of PTHrP using Graphpad Prism 5. p-values are indicated. Presented graphs are representative 
examples of three independent experiments.
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moments in differentiation. To maintain Rmrp knockdown during an extended period of time during chondro-
genic differentiation, siRNAs were either transfected on day 2 and 5 in chondrogenic differentiation for read-out 
at day 7 or on day 2, 5 and 8 in chondrogenic differentiation for read-out at day 14. Rmrp RNA knockdown 
resulted in reduced Rmrp RNA expression at day 7 in chondrogenic differentiation (Fig. 7A). Since day 14 cells 
were last transfected at day 8 in chondrogenic differentiation, Rmrp RNA expression was almost back to baseline 
levels in the day 14 Rmrp RNA knockdown condition (Fig. 7A). Rmrp RNA knockdown resulted in reduced cell 
numbers, inferring reduced proliferation (quantified in Fig. 7B and visually depicted in Fig. 7C,D). Rmrp RNA 
knockdown led to a significant reduction of GAG content at day 7 and this was still detectable at day 14 in chon-
drogenic differentiation (Fig. 7E). GAG content at day 14 before extraction of the Alcian Blue dye is visualized in 
Fig. 7F. Mineralization, quantified by Alizarin Red staining was reduced at day 7 and day 14 in chondrogenic dif-
ferentiation (Fig. 7G) and visualized in Fig. 7H,I. In concert with the Alizarin Red data, ALP enzyme activity was 
almost absent at day 7 in chondrogenic differentiation as a result of Rmrp knockdown and was still significantly 
reduced at day 14 in chondrogenic differentiation (Fig. 7J).
Chondrogenic trans-differentiation is impaired in CHH fibroblasts. CHH is caused by mutations 
in RMRP RNA14, 17, but it is unknown whether these mutations influence chondrogenic differentiation in CHH 
patients. To test whether the chondrogenic capacity of CHH cells is impaired, we employed a trans-differentiation 
protocol that drives dermal fibroblasts towards a chondrocyte-like phenotype34. High density plating of fibro-
blasts on an Aggrecan-coated surface in the presence of TGFβ3 induced the formation of dense aggregates within 
24 hours post-plating, resembling chondrogenic nodules. To focus on functional chondrogenic read-out markers 
we measured induction of COL10A1, COL2A1 and ALPL (alkaline phosphatase) gene expression in cultures from 
healthy fibroblasts, substantiating trans-differentiation into the chondrogenic lineage (Fig. 8A–C). Induction of 
COL10A1 expression was more robust than COL2A1, which indicates that these cultures display a predominant 
hypertrophic phenotype (Fig. 8A,B). As a result of the chondrogenic trans-differentiation RMRP RNA expres-
sion levels increased (Fig. 8D). Compared to healthy control cultures we found that CHH fibroblasts (4 CHH 
patients, carrying different CHH pathogenic mutations in the RMRP gene (i.e. 127 G > A and 261 C > G; 4 C > T 
and 77 C > T; 70 A > G and 70 A > G; 4 C > T and -21_-9dup CTCTGTGAAGCTG)) displayed an impaired 
induction of COL10A1 and ALPL expression upon chondrogenic trans-differentiation (Fig. 8B,C). Induction 
of COL2A1 expression was not affected at day 3 in trans-differentiation. At days 5 and 7 during chondrogenic 
trans-differentiation, COL2A1 expression appeared lower in CHH fibroblasts as compared to healthy controls 
(Fig. 8A), although this difference was not significant. The induction of RMRP RNA expression observed in 
healthy control fibroblasts was absent in CHH cultures (Fig. 8D). Moreover, and in concert with the observed 
impaired hypertrophic differentiation (Fig. 8B,C), the expression of PTHrP was increased in CHH cultures as 
compared to healthy control cultures (Fig. 8E). Finally, we detected a significant increase in the accumulation of 
Figure 5. Rmrp promoter activity is altered by chondrogenic morphogens. Rmrp promoter responsiveness to 
different chondrogenic morphogens and pathways was determined by transfection of the pGluc-Rmrp-prom 
reporter plasmid, comprising the 1500 nucleotide sequence upstream of the mouse Rmrp RNA transcription 
start site. ATDC5 cells were transiently co-transfected with this reporter and pGL4.20[luc2/Puro]-CMV to 
normalize for transfection efficiency. Transfected cells were exposed for 24 hours to either 100 nM PTHrP, 
15 ng/ml bFGF, 10 ng/ml TGFβ3, 0.5 μM (5Z)-7-Oxozeaenol, 30 ng/ml BMP-2, 10 μM dorsomorphin, 100 ng/
ml GDF-5, 15 ng/ml WNT-3A, 15 ng/ml WNT-5A or 150 ng/ml SHH. These concentrations were chosen 
based on their use as described in literature. Promoter activity is depicted as fold induction relative to control. 
Data was normalized to pGL4.20[luc2/Puro]-CMV and represents the average value of 4 biological replicates 
plus standard deviation. For statistical evaluation an independent samples t-test was performed relative to 
control using GraphPad Prism 5. p-values are indicated. Presented graphs are representative examples of three 
independent experiments.
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the ITS1 pre-rRNA processing intermediate4 (Fig. 8F). Together, data show that in CHH fibroblasts chondrogenic 
trans-differentiation is impaired with a major impact on hypertrophic development of these cultures.
Discussion
The involvement of the RMRP lncRNA in the pathophysiology of CHH has previously been identified17; however 
it is not clear why mutations in RMRP RNA lead to a severe skeletal dysplasia phenotype. Skeletal development 
depends on chondrogenic differentiation in the growth plate and therefore we hypothesized that RMRP RNA has 
a functional role during chondrogenic differentiation, explaining the dwarfism that characterizes CHH patients. 
We found that expression levels of RMRP RNA and RNase MRP protein subunits are induced and spatiotempo-
rally regulated during the course of chondrogenic differentiation. RMRP expression levels are especially induced 
during the hypertrophic phase of chondrogenic differentiation, indicating an increased demand for RMRP RNA 
levels during this phase of the differentiation process. As long as the substrate(s) of RNase MRP that are involved 
in the molecular mechanisms of chondrogenic differentiation has/have not been identified, we can only specu-
late how induction of RMRP RNA expression is associated with chondrocyte hypertrophy. It is remarkable that 
in CHH tissues with fast-dividing cell types (growth plate, hair follicles, bone marrow etc.) seem to be the most 
affected ones16, suggesting a role for RMRP RNA in cell cycle regulation. Tight control over cell mitosis and 
differentiation is paramount to controlling growth plate development47. The proliferative zone of the growth 
plate presents a high mitotic activity, while terminally differentiated chondrocytes in the hypertrophic zone most 
likely lack a mitotic cycle. One of the identified activities of the RNase MRP complex is endoribonucleolytic 
cleavage of the mRNA of cyclin b2 (Clb2). This B-type cyclin activates cyclin-dependent kinase-1 (CDK1) during 
M-phase and anaphase-promoting complex (APC)-dependent proteolysis of Clb2 is essential for mitotic exit48. 
Low Clb2 levels also keep CDK1 activity to a minimum during G0 phase via similar APC-dependent proteoly-
sis49. It is likely that the strictly regulated terminal differentiation of hypertrophic chondrocytes is orchestrated by 
Figure 6. Rmrp RNA knockdown deregulates ATDC5 chondrogenic differentiation. ATDC5 cells were 
transfected with 100 nM siRNA duplex targeting Rmrp RNA expression on day -1, day 2, and day 5 during 
chondrogenic differentiation. A scrambled siRNA was used as control condition. RNA was isolated from 
these cultures at day 7 and 10 in differentiation and at t = 0 as a reference. Expression of Rmrp (A), Clb2 (B), 
Viperin (C), ITS1 rRNA processing intermediate (D), Sox9 (E), Col2a1 (F), Runx2 (G), Col10a1 (H), Alpl (I), 
Bapx1 (J), PthrP (K) and Rmrp, 18S, 5.8S and 28S (L) was determined by means of RT-qPCR. Gene expression 
is depicted as fold induction relative to t = 0 (A–K). In Fig. 6L day 7 scrambled controls are set to 1. Data was 
normalized to β-actin and represents the average value of 3 (Fig. 6A–K) or 4 (Fig. 6L) biological replicates plus 
standard deviation. For statistical evaluation an independent samples t-test was performed relative to scrambled 
control for each consecutive time point using GraphPad Prism 5. p-values are indicated. Presented graphs are 
representative examples of three independent experiments.
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mitotic exit or entrance into G0 phase. As RNase MRP activity has been shown to degrade the Clb2 message it is 
tempting to speculate that the elevation of RNase MRP levels during chondrocyte hypertrophy serves to decrease 
Figure 7. Rmrp RNA knockdown reduces cell proliferation, glycosaminoglycan content and mineralization. 
ATDC5 cells were transfected with siRNA duplex targeting Rmrp RNA on day 2 and 5 in differentiation (30 
and 100 nM, respectively) and analyzed on day 7. In addition differentiating ATDC5 cells were transfected with 
the Rmrp RNA siRNA at day 2, 5 and 8 (30 nM, 100 nM and 100 nM, respectively) and analyzed at day 14 in 
differentiation. A scrambled siRNA was used as a control. Knockdown of Rmrp RNA expression was confirmed 
by RT-qPCR (A). Cell proliferation was determined by extraction and spectrophotometric analysis of bound 
Crystal Violet staining (B); staining before dye extraction is shown in (C) and (D). Glycosaminoglycan content 
was determined by extraction of Alcian Blue staining (E); day 14 staining before dye extraction is shown in 
(F). Mineralization was determined by extraction of Alizarin Red staining (G); staining before dye extraction 
is visualized in (H) and (I). ALP activity in μmol/g/min, corrected for total protein was determined in (J). 
Data (A,B,E,G,J) represents the average value of 4 biological replicates plus standard deviation and scrambled 
control is set to 1 (A,B,E,G). In graph (J) ALP activity in μmol/g/min was corrected for total protein levels. For 
statistical evaluation (A,B,E,G,J) an independent samples t-test was performed relative to scrambled control 
for each consecutive time point using GraphPad Prism 5. p-values are indicated. In (C,D,F,H,I) the upper 
panels show 4 biological replicates ‘Scr’ = Scrambled siRNA and the lower panels show 4 biological replicates 
‘siRmrp’ = Rmrp siRNA.
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Clb2 protein levels by increased turnover of Clb2 mRNA to inhibit activation of CDK1. Compelling evidence 
from recent work indeed shows the crucial involvement of CDK1 in controlling chondrocyte hypertrophic dif-
ferentiation50. CDK1 expression was found to be highly expressed in proliferative chondrocytes and was greatly 
diminished in hypertrophic chondrocytes in differentiating ATDC5 cultures, as well as in mouse growth plates. In 
addition genetic interference with CDK1 expression caused absence of proliferative chondrocytes in the growth 
plate and a switch towards hypertrophic differentiation in ATDC5 cultures, strongly suggesting that the reduc-
tion of CDK1 levels or its decreased activity is a prerequisite for hypertrophic differentiation. We thus specu-
late that in a healthy growth plate the increased RMRP RNA levels in hypertrophic chondrocytes may lead to 
decreased Clb2 levels, thereby hampering CDK1 activity and inducing an overall mitotic arrest. Work from the 
same group50 shows that the proliferation-promoting and hypertrophy-suppressive action of PTHrP is, at least 
in part, CDK1-dependent. In agreement with this notion we observed that Rmrp RNA levels are down regulated 
upon PTHrP exposure, presumably via decreased Rmrp promoter transcriptional activity. This may result in ele-
vated Clb2 levels, thereby potentially aiding in PTHrP downstream CDK1 activity. In this respect, it is important 
to note that knockdown of Rmrp RNA levels during ATDC5 chondrogenic differentiation increases Clb2 and 
Pthrp mRNA levels and deregulates chondrogenic differentiation in an overall hypertrophy-suppressing fashion. 
One of the earliest identified roles of RNase MRP is endoribonucleolytic maturation of 5.8 S rRNA by cleaving site 
A3 in the internal transcribed spacer 1 (ITS1) in yeast3, 4. Even though there is presently no conclusive evidence 
showing that specifically hypertrophic chondrocytes in the growth plate display the highest protein synthetic 
capacity, an RMRP RNA/RNase MRP mediated contribution to the synthesis of the large ribosomal subunit in 
the growth plate may support the high protein synthetic activity of the growth plate to produce protein-rich car-
tilaginous extracellular matrix. For long an involvement of RNase MRP in the processing of ITS1 in human cells 
remained elusive51. However, recently it has been elegantly shown that human RMRP RNA in the RNase MRP 
complex indeed catalyzes the endoribonucleolytic cleavage of ITS1, thereby contributing to pre-rRNA matura-
tion4. Indeed our RMRP RNA knockdown data in ATDC5 show accumulation of an ITS1 pre-rRNA processing 
intermediate as well as reduced levels of mature 5.8 S and 18 S rRNA. In concert with these findings we detected 
similar accumulation of an ITS1 processing intermediate in differentiating CHH cells. Chondrogenic differentia-
tion of ATDC5 and the developing growth plate is associated with high proliferative capacity31 and increased syn-
thesis of protein-rich ECM. It is conceivable that this alters the cellular demand for mature rRNAs for ribosome 
Figure 8. Impaired chondrogenic differentiation and increased ITS1 expression during chondrogenic trans-
differentiation of CHH fibroblasts. Human dermal fibroblasts from four CHH patients (RMRP alleles of CHH 
patients carried the following mutations: 127 G > A and 261 C > G (circle); 4 C > T and 77 C > T (square); 
70 A > G and 70 A > G (triangle); 4 C > T and -21_-9dup CTCTGTGAAGCTG (diamond)) and three healthy 
controls (individual gene expression data points for each healthy control and patient are indicated) were trans-
differentiated into the chondrogenic lineage by hyperconfluent plating in wells coated with Aggrecan. Total 
RNA was isolated at days 0 (non-plated fibroblasts), 3, 5 and 7 in trans-differentiation and gene expression of 
COL2A1 (A), COL10A1 (B), ALPL (C), RMRP (D), PTHrP (E) and ITS1 (F) was determined by RT-qPCR. 
Data was normalized to GAPDH and represents the mean plus standard deviation; gene expression data is set 
relative to day 0 healthy control. For statistical evaluation an independent samples t-test was performed relative 
to healthy control for each individual time point using GraphPad Prism 5. p-values are indicated. Graphs are 
representative examples of three independent experiments.
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biogenesis, potentially explaining the changes in Rmrp RNA expression during chondrogenic differentiation and 
the phenotype observed after Rmrp RNA knockdown. Finally, RMRP RNA has been described to associate with 
TERT7, the reverse transcriptase that is associated with the telomerase holoenzyme. This RMRP RNA-containing 
macromolecular complex was demonstrated to display RNA-dependent RNA polymerase activity. This activity 
generates a double-stranded RMRP RNA molecule that is converted by Dicer into an siRNA that targets RMRP 
RNA7, as well as specific mRNAs52. Other RMRP RNA-derived siRNAs have been identified as well, but it is cur-
rently unknown whether these are also generated via a similar mechanism. The latter siRNAs, termed RMRP-S1 
and RMRP-S28, seem to target genes relevant for skeletal development like SOX4, PTCH2 and BMPR2. It remains 
elusive whether this relates to increased RMRP RNA levels in hypertrophic chondrocytes, but it is conceivable 
that upregulation of RMRP RNA leads to higher production of RMRP-S1 and RMRP-S2, which in turn may 
change the magnitude by which RMRP-S1 and RMRP-S2 targets are influenced.
Our observations that the expression of RNase MRP components is modulated in differentiating cells pro-
moted us to investigate whether RMRP RNA expression levels can be controlled at the transcriptional level. 
RMRP RNA expression is driven by RNA polymerase III (RNAPIII) and the proximal RMRP RNA promoter 
has been studied in the past to some extent53, showing that the −84 bp promoter region is sufficient to drive 
RNAPIII-dependent transcription of RMRP RNA. However, to fine-tune promoter activity and to be able to 
respond to alternating demands of RMRP RNA (e.g. during chondrocyte hypertrophy), it is expected that addi-
tional transcription regulatory elements are present. Indeed, WNT-3A was recently found to be able to drive 
RMRP transcription in cancer via activation of β-catenin and YAP proteins54. Here, we showed that the 1500 base 
pair sequence upstream of the Rmrp RNA transcription start site is responsive to a series of chondrocyte mor-
phogens or pathways. Several of the growth factors tested increased or decreased the transcriptional activity of 
the minus 1500 Rmrp promoter, indeed indicating that in chondrocytic cells transcription of Rmrp RNA may be 
under transcriptional control of chondrogenic cues. In agreement with their known role in chondrocyte hyper-
trophy45, WNT-5A, WNT-3A and BMP-2 induced Rmrp promoter activity, suggesting that increased Rmrp RNA 
expression in chondrocyte hypertrophy is, at least in part, transcriptionally controlled by one or more of these 
morphogens and their downstream pathways. Indeed, in silico prediction of putative transcription factor binding 
sites in the minus 1500 bp Rmrp promoter sequence suggests the presence of CREB, MEF2, TCF/LEF and SMAD 
binding sites (Genomatix; data not shown) which are transcription factors acting downstream of WNT-5A, 
WNT-3A and BMP-2 signaling. Dorsomorphin (a BMP/SMAD1/5/8 inhibitor) exposure greatly reduced Rmrp 
promoter activity, further supporting BMP-mediated control of RMRP transcription. In keeping with a potential 
feedback mechanism it is noteworthy that BMPR2 (the type II BMP receptor) is a potential target of RMRP-S2, 
the RMRP RNA-derived siRNA8.
Active control over Rmrp transcription in chondrocyte hypertrophy is further substantiated by the obser-
vation that PTHrP and bFGF are able to reduce Rmrp promoter activity. PTHrP and bFGF delay chondrocyte 
hypertrophy/terminal differentiation23, 38, 39, 55. At this point we can only speculate whether reduced Rmrp pro-
moter activity and Rmrp expression by PTHrP and bFGF is an indirect result of a morphogen-dependent chang-
ing chondrocyte hypertrophic phenotype (e.g. decreased WNT or BMP signaling), or that these morphogens 
directly control Rmrp abundance by downstream inhibition of Rmrp promoter activity. We conclude that Rmrp 
transcription in chondrocytes is controlled by well-known chondrogenic signaling pathways that are associated 
with hypertrophic differentiation. It remains to be determined whether such transcriptional control is also pres-
ent in other cell types and how this communicates with the RNAPIII transcription machinery56.
The clinical presentation of CHH is dominated by short stature, caused by impaired skeletal development. Our 
data are consistent with a pivotal role for RMRP RNA during chondrogenic differentiation and is especially linked 
to chondrocyte hypertrophic differentiation. Genetic interference with Rmrp RNA expression in ATDC5 cells and 
chondrogenic trans-differentiation of CHH fibroblasts indicates delayed chondrocyte hypertrophy. Growth plates 
of CHH patients are characterized by delayed ossification and the presence of very few hypertrophic chondro-
cytes25. Whether and how delayed chondrocyte hypertrophy may influence the development of the growth plate 
in CHH remains to be determined. Finally, considering our observations that the expression of PTHrP is induced 
during knockdown of Rmrp RNA and in chondrogenic differentiating CHH fibroblasts and its inhibiting action 
on RMRP promoter activity and RMRP RNA expression, it is interesting to realize that disrupted PTH/PTHrP 
signaling is deleterious for skeletal development by endochondral ossification57. Considering this it is tempting to 
speculate whether there are molecular connections between RMRP RNA and PTH/PTHrP in skeletal dysplasias 
like cartilage-hair hypoplasia, metaphyseal chondrodysplasia Jansen type (OMIM #156400)58 and Blomstrand 
type chondrodysplasia59, (OMIM #215045).
In conclusion, lncRNAs involved in mesenchymal cellular differentiation processes are scarcely known60 and 
we found that the RMRP lncRNA is differentially expressed during different stages of chondrogenic differenti-
ation and displaying a prominent association with chondrocyte hypertrophic development. Our findings shed 
new light on potential pathobiological mechanisms involved in the skeletal dysplasia phenotype associated with 
cartilage-hair hypoplasia.
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